Evidence map›Paper›PMID 34627371›Full record

ArticleAlzheimer's research & therapy2021

Visuospatial memory impairment as a potential neurocognitive marker to predict tau pathology in Alzheimer's continuum.

Eun Hyun Seo, Ho Jae Lim, Hyung-Jun Yoon, Kyu Yeong Choi, Jang Jae Lee, Jun Young Park, Seong Hye Choi, Hoowon Kim, Byeong C Kim, Kun Ho Lee

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Eun Hyun Seo *Gwangju Alzheimer's Disease and Related Dementia Cohort Research Center, Chosun University, 61452, Gwangju, Republic of Korea.
Ho Jae Lim *Gwangju Alzheimer's Disease and Related Dementia Cohort Research Center, Chosun University, 61452, Gwangju, Republic of Korea.
Hyung-Jun Yoon *Department of Neuropsychiatry, College of Medicine, Chosun University, Gwangju, 61452, Republic of Korea.
Kyu Yeong ChoiGwangju Alzheimer's Disease and Related Dementia Cohort Research Center, Chosun University, 61452, Gwangju, Republic of Korea.
Jang Jae LeeGwangju Alzheimer's Disease and Related Dementia Cohort Research Center, Chosun University, 61452, Gwangju, Republic of Korea.
Jun Young ParkDepartment of Public Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, 08826, Republic of Korea.
Seong Hye ChoiDepartment of Neurology, Inha University School of Medicine, Incheon, 22212, Republic of Korea.
Hoowon KimDepartment of Neurology, Chosun University Hospital, Gwangju, 61452, Republic of Korea.
Byeong C KimDepartment of Neurology, Chonnam National University Medical School, Gwangju, 61469, Republic of Korea.
Kun Ho LeeGwangju Alzheimer's Disease and Related Dementia Cohort Research Center, Chosun University, 61452, Gwangju, Republic of Korea. leekho@chosun.ac.kr.ORCID 0000-0003-4144-8162
Chosun University · KRChonnam National University Hospital · KRChosun University Hospital · KRInha University · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGiven that tau accumulation, not amyloid-β (Aβ) burden, is more closely connected with cognitive impairment in Alzheimer's disease (AD), a detailed understanding of the tau-related characteristics of cognitive function is critical in both clinical and research settings. We investigated the association between phosphorylated tau (p-Tau) level and cognitive impairment across the AD continuum and the mediating role of medial temporal lobe (MTL) atrophy. We also developed a prediction model for abnormal tau accumulation.

methodsWe included participants from the Gwangju Alzheimer's Disease and Related Dementia Cohort in Korea, who completed cerebrospinal fluid analysis and clinical evaluation, and corresponded to one of three groups according to the biomarkers of A and T profiles based on the National Institute on Aging and Alzheimer's Association research framework. Multiple linear and logistic regression analyses were performed to examine the association between p-Tau and cognition and to develop prediction models. Receiver operating characteristic curve analysis was performed to examine the discrimination ability of the models.

resultsAmong 185 participants, 93 were classified as A-T-, 23 as A+T-, and 69 as A+T+. There was an association between decreased visuospatial delayed memory performance and p-Tau level (B = - 0.754, β = - 0.363, p < 0.001), independent of other relevant variables (e.g., Aβ). MTL neurodegeneration was found to mediate the association between the two. Prediction models with visuospatial delayed memory alone (area under the curve [AUC] = 0.872) and visuospatial delayed memory and entorhinal thickness (AUC = 0.921) for abnormal tau accumulation were suggested and they were validated in an independent sample (AUC = 0.879 and 0.891, respectively).

conclusionIt is crucial to identify sensitive cognitive measures that capture subtle cognitive impairment associated with underlying pathological changes. Preliminary findings from the current study might suggest that abnormal tau accumulation underlies episodic memory impairment, particularly visuospatial modality, in the AD continuum. Suggested models are potentially useful in predicting tau pathology, and might be utilized practically in the field.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesBiomarkersHumansMemory Disorderstau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer’s diseaseATN classificationBiomarkersCerebrospinal fluidTauVisuospatial memory

Identifiers

PMID34627371
PMCPMC8502282
OpenAlexW3205670550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.